{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Neoplasm&page=39",
    "query": {
      "condition": "Follicular Neoplasm",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 1364,
    "total_pages": 137,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Neoplasm&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Neoplasm&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T16:02:27.922Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04007029",
      "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "CD19 Positive",
        "CD20 Positive",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Follicular Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma",
        "Refractory Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Chimeric Antigen Receptor T-Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-10-04",
      "completion_date": "2028-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-30T16:02:27.922Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04007029"
    },
    {
      "nct_id": "NCT06815029",
      "title": "Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Astrocytoma, IDH-Mutant, Grade 3",
        "Recurrent Astrocytoma, IDH-Mutant, Grade 4",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Chimeric Antigen Receptor T-Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Echocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Intracranial Catheter Placement",
          "type": "PROCEDURE"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Resection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-06-17",
      "completion_date": "2030-10-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-30T16:02:27.922Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06815029"
    },
    {
      "nct_id": "NCT06854159",
      "title": "Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Chimeric Antigen Receptor T-Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Odronextamab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2025-08-07",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-10-30T16:02:27.922Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06854159"
    },
    {
      "nct_id": "NCT00006083",
      "title": "Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cervical Cancer",
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Precancerous/Nonmalignant Condition",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Veno-occlusive Disease"
      ],
      "interventions": [
        {
          "name": "Fragmin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-04",
      "completion_date": "2000-11",
      "has_results": false,
      "last_update_posted_date": "2020-08-03",
      "last_synced_at": "2026-10-30T16:02:27.922Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006083"
    },
    {
      "nct_id": "NCT03579927",
      "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "CD19 Positive",
        "Mantle Cell Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Follicular Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Umbilical Cord Blood-derived Natural Killer Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-10-03",
      "completion_date": "2019-10-03",
      "has_results": false,
      "last_update_posted_date": "2020-01-29",
      "last_synced_at": "2026-10-30T16:02:27.922Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03579927"
    },
    {
      "nct_id": "NCT00946283",
      "title": "Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Lactobacillus rhamnosus GG",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 30,
      "start_date": "2010-03",
      "completion_date": "2015-10-14",
      "has_results": false,
      "last_update_posted_date": "2017-02-03",
      "last_synced_at": "2026-10-30T16:02:27.922Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00946283"
    },
    {
      "nct_id": "NCT03842696",
      "title": "Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Diseases",
        "Acute Leukemia in Remission",
        "Chronic Myelogenous Leukemia - Chronic Phase",
        "Chronic Myelogenous Leukemia, Accelerated Phase",
        "Chronic Myelogenous Leukemia, Blastic Phase",
        "Myelodysplastic Syndromes",
        "Mantle Cell Lymphoma",
        "Follicular Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Non Hodgkin Lymphoma",
        "Graft Vs Host Disease",
        "Graft-versus-host-disease"
      ],
      "interventions": [
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Blood and Marrow Transplant (BMT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus (or cyclosporine)",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "3 Years to 39 Years"
      },
      "enrollment_count": 43,
      "start_date": "2020-02-04",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-10-30T16:02:27.922Z",
      "location_count": 7,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03842696"
    },
    {
      "nct_id": "NCT00438880",
      "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Nodal Marginal Zone Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Agatolimod Sodium",
          "type": "DRUG"
        },
        {
          "name": "Indium In-111 Ibritumomab Tiuxetan",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Radionuclide Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single Photon Emission Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Yttrium Y-90 Ibritumomab Tiuxetan",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2004-10",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2016-02-04",
      "last_synced_at": "2026-10-30T16:02:27.922Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Rochester, Minnesota",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00438880"
    },
    {
      "nct_id": "NCT00126646",
      "title": "BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "BL22 immunotoxin",
          "type": "DRUG"
        },
        {
          "name": "antibody-drug conjugate therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "immunotoxin therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2005-06",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2010-06-22",
      "last_synced_at": "2026-10-30T16:02:27.922Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00126646"
    },
    {
      "nct_id": "NCT00608361",
      "title": "Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Adult B Acute Lymphoblastic Leukemia",
        "Adult Hepatocellular Carcinoma",
        "Adult Nasal Type Extranodal NK/T-Cell Lymphoma",
        "Adult Solid Neoplasm",
        "Adult T Acute Lymphoblastic Leukemia",
        "Advanced Adult Hepatocellular Carcinoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-Cell Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Cutaneous B-Cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Hepatosplenic T-Cell Lymphoma",
        "Intraocular Lymphoma",
        "Localized Non-Resectable Adult Liver Carcinoma",
        "Localized Resectable Adult Liver Carcinoma",
        "Lymphomatous Involvement of Non-Cutaneous Extranodal Site",
        "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Nodal Marginal Zone Lymphoma",
        "Progressive Hairy Cell Leukemia Initial Treatment",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Lymphoma",
        "Recurrent Adult Liver Carcinoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-Cell Leukemia/Lymphoma",
        "Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides and Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Small Intestinal Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Stage II Small Lymphocytic Lymphoma",
        "Stage III Adult Burkitt Lymphoma",
        "Stage III Adult Diffuse Large Cell Lymphoma",
        "Stage III Adult Diffuse Mixed Cell Lymphoma",
        "Stage III Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage III Adult Hodgkin Lymphoma",
        "Stage III Adult Immunoblastic Lymphoma",
        "Stage III Adult Lymphoblastic Lymphoma",
        "Stage III Adult T-Cell Leukemia/Lymphoma",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Stage III Grade 1 Follicular Lymphoma",
        "Stage III Grade 2 Follicular Lymphoma",
        "Stage III Grade 3 Follicular Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage III Marginal Zone Lymphoma",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IIIA Mycosis Fungoides and Sezary Syndrome",
        "Stage IIIB Mycosis Fungoides and Sezary Syndrome",
        "Stage IV Adult Burkitt Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Mixed Cell Lymphoma",
        "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage IV Adult Hodgkin Lymphoma",
        "Stage IV Adult Immunoblastic Lymphoma",
        "Stage IV Adult Lymphoblastic Lymphoma",
        "Stage IV Adult T-Cell Leukemia/Lymphoma",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Stage IV Grade 1 Follicular Lymphoma",
        "Stage IV Grade 2 Follicular Lymphoma",
        "Stage IV Grade 3 Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma",
        "Stage IV Marginal Zone Lymphoma",
        "Stage IV Small Lymphocytic Lymphoma",
        "Stage IVA Mycosis Fungoides and Sezary Syndrome",
        "Stage IVB Mycosis Fungoides and Sezary Syndrome",
        "T-Cell Large Granular Lymphocyte Leukemia",
        "Testicular Lymphoma",
        "Untreated Adult Acute Lymphoblastic Leukemia",
        "Untreated Hairy Cell Leukemia",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2008-10",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2015-07-02",
      "last_synced_at": "2026-10-30T16:02:27.922Z",
      "location_count": 23,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 14 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Hays",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00608361"
    }
  ]
}